AMGN vs SEPN
AMGN: Amgen is a leading biotechnology firm dedicated to developing innovative human therapeutics to address critical unmet needs in areas like oncology, inflammation, and cardiovascular disease. SEPN: Septerna is a biotechnology company pioneering a new approach to unlock the therapeutic potential of G protein-coupled receptors (GPCRs) through oral small molecule drug discovery.
Side-by-side fundamentals
| Metric | AMGN | SEPN | Edge |
|---|---|---|---|
| Price as of 2026-08-25 close | $442.24 | $41.30 | |
| Market cap as of 2026-08-26 | $239.1B | $1.9B | |
| P/E as of 2026-08-26 | 25.84 | n/a | |
| PEG as of 2026-08-26 | 5.48 | n/a | |
| Net margin as of 2026-08-26 | +22.9% | -49.9% | AMGN higher |
| Gross margin as of 2026-08-26 | +74.3% | n/a | |
| Operating margin as of 2026-08-26 | +30.3% | -77.1% | AMGN higher |
| ROE as of 2026-08-26 | +89.3% | -9.4% | AMGN higher |
| ROA as of 2026-08-26 | +9.5% | -6.6% | AMGN higher |
| Debt / equity as of 2026-08-26 | 4.90 | 0.00 | SEPN lower |
| Revenue growth (YoY) as of 2026-08-26 | +9.1% | +11790.1% | SEPN higher |
| Revenue CAGR (3y) SEC XBRL | +11.8% | +1644.5% | SEPN higher |
| Dividend yield as of 2026-08-26 | +3.2% | n/a | |
| Dividend streak (yrs) SEC XBRL | 5 | n/a | |
| Beta as of 2026-08-26 | 0.42 | 0.80 | |
| 1-year return as of 2026-08-25 close | +53.3% | +245.3% | SEPN higher |
Fundamentals: market data, as of 2026-08-26. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-25.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.